JNJ
Johnson & Johnson operates as a holding company with approximately 138,200 employees developing, manufacturing, and selling healthcare products globally across two segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on prescription drugs across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular/metabolic conditions, with marketed products including CAR-T cell therapies, monoclonal antibodies, bispecific antibodies, and small-molecule inhibitors at various clinical stages. Products are distributed through retailers, wholesalers, hospitals, and healthcare professionals.
Pipeline
Chimeric anti-EGFR monoclonal antibody (Erbitux) that blocks EGFR signaling and triggers ADCC. Approved in metastatic colorectal cancer (KRAS wild-type) and head and neck cancer.
Anti-PD-L1 monoclonal antibody (Imfinzi) that blocks PD-L1, restoring T-cell anti-tumor activity. Approved in NSCLC, SCLC, biliary tract cancer, and hepatocellular carcinoma.